AbbVie (ABBV) Accounts Payables (2012 - 2026)

AbbVie (ABBV) has reported Accounts Payables for 15 consecutive years, with $33.3 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accounts Payables rose 3.27% year-over-year to $33.3 billion in Q2 2026; TTM through Jun 2026 was $33.3 billion, a 3.27% increase from a year earlier, with the FY2025 full-year figure at $34.7 billion, up 8.73% from the prior year.
• Accounts Payables was $33.3 billion for Q2 2026 at AbbVie, down from $33.8 billion in the prior quarter.
• Over five years, Accounts Payables peaked at $34.7 billion in Q4 2025 and troughed at $22.5 billion in Q2 2022.
• A 5-year average of $29.3 billion and a median of $30.6 billion in 2023 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables rose 26.37% in 2024 and retreated 0.91% in 2025, its largest moves.
• Over 5 years, Accounts Payables stood at $25.4 billion in 2022, then grew by 20.66% to $30.6 billion in 2023, then grew by 4.23% to $31.9 billion in 2024, then gained by 8.73% to $34.7 billion in 2025, then dropped by 4.13% to $33.3 billion in 2026.
• The last three Accounts Payables figures came in at $33.3 billion (Q2 2026), $33.8 billion (Q1 2026), and $34.7 billion (Q4 2025), per Business Quant data.